VENTANA PD-L1 (SP263) Assay

Guiding immunotherapy for urothelial carcinoma

Have any questions?
Contact us

VENTANA PD-L1 predictive assays assess the degree and likelihood of potential patient benefit from corresponding PD-1/PD-L1 immunotherapies. The link between assay results and patient benefit has been established and verified in studies. 


VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying: 

Urothelial carcinoma (UC) patients most likely to benefit from IMFINZI (durvalumab)[FDA approved in the US]


The PD-L1 immunologic checkpoint 

About PD-L1

The tumor microenvironment